Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Informe acción SEHK:1349

Capitalización de mercado: HK$7.2b

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Dividendos y recompras

Dividendo controles de criterios 0/6

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd es una empresa que paga dividendos con una rentabilidad actual de 1.6%.

Información clave

1.6%

Rentabilidad por dividendo

0%

Rendimiento de la recompra

Rendimiento total para el accionista1.6%
Rendimiento futuro de los dividendosn/a
Crecimiento de los dividendos11.5%
Próxima fecha de pago de dividendosn/a
Fecha ex dividendon/a
Dividendo por acciónHK$0.0436
Ratio de pago94%

Últimas actualizaciones de dividendos y recompras

Recent updates

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's (HKG:1349) Problems Go Beyond Poor Profit

Nov 04
Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's (HKG:1349) Problems Go Beyond Poor Profit

There's Reason For Concern Over Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.'s (HKG:1349) Massive 51% Price Jump

Oct 14
There's Reason For Concern Over Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.'s (HKG:1349) Massive 51% Price Jump

Earnings Troubles May Signal Larger Issues for Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd (HKG:1349) Shareholders

May 06
Earnings Troubles May Signal Larger Issues for Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd (HKG:1349) Shareholders

What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend

Apr 12
What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend

We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease

Mar 22
We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease

Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Mar 07
Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?

Feb 20
Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?

Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?

Feb 07
Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?

Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?

Jan 25
Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?

Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?

Jan 12
Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?

Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?

Dec 28
Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly

Dec 15
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly

Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Dec 03
Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Nov 21
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: 1349 no paga un dividendo notable para el mercado Hong Kong, por lo que no es necesario comprobar si los pagos son estables.

Dividendo creciente: 1349 no paga un dividendo notable para el mercado Hong Kong, por lo que no es necesario comprobar si los pagos aumentan.


Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd vs. Mercado
¿Cómo se compara la rentabilidad por dividendo de 1349 con la del mercado?
SegmentoRentabilidad por dividendo
Empresa (1349)1.6%
Suelo de mercado 25% (HK)3.2%
Techo de mercado 25% (HK)8.0%
Media de la industria (Pharmaceuticals)3.8%
Analista de previsiones (1349) (hasta 3 años)n/a

Dividendo destacado: El dividendo de 1349(1.6%) no es notable en comparación con el 25% inferior de pagadores de dividendos del mercado Hong Kong (3.22%).

Alto dividendo: El (1.6%) del dividendo de 1349 es bajo en comparación con el 25% de los principales pagadores de dividendos del mercado Hong Kong (8.04%).


Pago de beneficios a los accionistas

Cobertura de los beneficios: 1349 no paga un dividendo notable para el mercado Hong Kong.


Pago en efectivo a los accionistas

Cobertura de flujo de caja: 1349 está pagando dividendo pero la empresa no tiene flujos de caja libre.


Descubre empresas que pagan buenos dividendos